PMID- 8093640
OWN - NLM
STAT- MEDLINE
DCOM- 19930217
LR  - 20190512
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 32
IP  - 1
DP  - 1993 Jan
TI  - Differential effects of tumor necrosis factor-alpha on proliferation, cell 
      surface antigen expression, and cytokine interactions in malignant gliomas.
PG  - 85-94
AB  - Tumor necrosis factor-alpha (TNF-alpha), a cytokine produced by astrocytes in 
      vivo and in vitro, was tested for its effects on two malignant astrocytoma cell 
      lines (A-172, U-87). Both lines were immunoreactive for glial fibrillary acidic 
      protein, vimentin, Class I antigens, and interleukin-6. The lines differed in 
      their expression of Class II and intercellular adhesion molecule-1 (ICAM-1) 
      antigenic determinants: A-172 cells were negative for both Class II and ICAM-1 
      antigens, while U-87 cells were intensely positive for Class II and weakly 
      positive for ICAM-1. When these astrocytoma cell lines were exposed to TNF-alpha, 
      A-172 growth was stimulated while U-87 growth was inhibited. Furthermore, in U-87 
      cells, TNF-alpha enhanced both ICAM-1 and interleukin-1 beta (IL-1 beta) 
      expression, and decreased immunoreactivity for transforming growth factor-beta 
      (TGF-beta) protein. In contrast, in the presence of TNF-alpha, A-172 cells 
      remained negative for IL-1 beta and TGF-beta, but showed an increased expression 
      of ICAM-1. These results demonstrate that TNF-alpha can induce changes in growth 
      rate, cytokine production, and surface antigen expression in malignant 
      astrocytomas; however, the nature of these changes is dependent on the specific 
      characteristics of these malignant astrocytomas. The resultant variability in the 
      immunological microenvironment of these tumors may reflect differences in their 
      growth potential.
FAU - Chen, T C
AU  - Chen TC
AD  - Department of Neurological Surgery, Los Angeles County Hospital/University of 
      Southern California Medical Center.
FAU - Hinton, D R
AU  - Hinton DR
FAU - Apuzzo, M L
AU  - Apuzzo ML
FAU - Hofman, F M
AU  - Hofman FM
LA  - eng
GR  - EY08144/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Cytokines)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-6)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
SB  - IM
MH  - Antigens, Neoplasm/*analysis
MH  - Brain Neoplasms/immunology/*pathology
MH  - Cell Adhesion Molecules/physiology
MH  - Cell Division/*physiology
MH  - Cell Line
MH  - Cytokines/*physiology
MH  - Glioblastoma/immunology/*pathology
MH  - Histocompatibility Antigens Class II/analysis
MH  - Humans
MH  - Immunophenotyping
MH  - Intercellular Adhesion Molecule-1
MH  - Interleukin-1/physiology
MH  - Interleukin-6/physiology
MH  - Transforming Growth Factor beta/physiology
MH  - Tumor Cells, Cultured/*immunology
MH  - Tumor Necrosis Factor-alpha/*physiology
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1227/00006123-199301000-00013 [doi]
PST - ppublish
SO  - Neurosurgery. 1993 Jan;32(1):85-94. doi: 10.1227/00006123-199301000-00013.